Zavante Therapeutics
Zavante is a late-stage biopharmaceutical company developing novel therapies to improve outcomes for hospitalized patients. Their lead product candidate, ZOLYD™, is an investigational, first-in-class injectable antibiotic aimed at combating serious, life-threatening infections caused by multi-drug resistant bacteria. Zavante focuses on addressing the urgent need for new antimicrobial agents, especially against MDR Gram-negative bacteria, with a pipeline that includes ZOLYD™ in various phases of development. The company is committed to developing innovative antibiotics with differentiated mechanisms of action to fill critical gaps in hospital infection treatment.
Industries
Nr. of Employees
small (1-50)
Products
Investigational intravenous fosfomycin antibiotic (IV fosfomycin development program)
An investigational IV fosfomycin-based antibiotic program under clinical development for treatment of serious hospital-acquired infections. Development activities include Phase 1 and pivotal Phase 2/3 clinical trials, PK/PD and population PK analyses, preclinical efficacy studies, and in vitro susceptibility and synergy evaluations.
Investigational intravenous fosfomycin antibiotic (IV fosfomycin development program)
An investigational IV fosfomycin-based antibiotic program under clinical development for treatment of serious hospital-acquired infections. Development activities include Phase 1 and pivotal Phase 2/3 clinical trials, PK/PD and population PK analyses, preclinical efficacy studies, and in vitro susceptibility and synergy evaluations.
Services
Collaborative agreements to support clinical pharmacology studies and trials, including provision of investigational drug product to trial sites and research networks.
Business development and partnering opportunities for licensing, co-development, and commercialization of investigational hospital-focused antibacterial therapies.
Collaborative agreements to support clinical pharmacology studies and trials, including provision of investigational drug product to trial sites and research networks.
Business development and partnering opportunities for licensing, co-development, and commercialization of investigational hospital-focused antibacterial therapies.
Expertise Areas
- Clinical trial management for infectious disease therapeutics
- Antibacterial drug development for hospitalized patients
- Clinical pharmacology and PK/PD modeling
- Microbiology and in vitro susceptibility testing
Key Technologies
- Population pharmacokinetic (popPK) modeling
- PK/PD target attainment analyses
- Minimum inhibitory concentration (MIC) testing
- Disk diffusion susceptibility testing